Combination approaches using IL-27 alongside TIM-3 or PD-1 checkpoint inhibitors might achieve superior outcomes compared to monotherapy approaches, which have shown limited efficacy in CLL [65,66]. The gene discussed is IL27; the disease is B-cell chronic lymphocytic leukemia.